Johnson & Johnson anticipates 14 new multibillion-dollar drugs by 2025
Category: #headlines  By Nikita Chaurasia  Date: 2021-11-20
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Johnson & Johnson anticipates 14 new multibillion-dollar drugs by 2025
  • Johnson & Johnson to focus on pharma division after the split into drug and consumer companies.
  • The company is working on 14 new drugs, all of which have a market potential of USD 1 billion each.  

American multinational corporation Johnson & Johnson (J&J) expects to petition for approval of 14 novel blockbuster drugs, each with potential for at least USD 1 billion in sales by 2025, execs stated during a strategy review of the company.

The move comes after the company announced its intention to spin off its consumer health business, which sells Listerine and Band-Aid bandages, to focus on pharmaceuticals and medical equipment. J&J is following the footsteps of several other pharmaceutical companies that have downscaled to focus on their pharmaceutical divisions.

Mathai Mammen, global head of research, J&J Janssen pharmaceutical division, mentioned that the company is developing an anticoagulant with partner Bristol Myers Squibb for non-small cell lung cancer, and a respiratory syncytial virus (RSV) vaccine.

He described them as the top pipeline assets the company has. Mammen also stated that he does not believe the deal will have a significant impact on R&D investment.

It is worth noting that J&J produced one of the three COVID-19 vaccines approved in the United States, however, its use in the country dropped drastically after its possible connection with rare incidences of blood clotting.

Nonetheless, J&J intends to produce more vaccines using the same viral vector technology, expressed Mammen.

The conglomerate was actively looking at various technological platforms, including messenger RNA, which is the backbone of Moderna and Pfizer's COVID-19 vaccines, and partner BioNTech's as well, he added.

Knowledgeable sources cited that Johnson & Johnson expects to be a USD 60 billion-a-year pharmaceutical company by 2025. The firm aims to generate revenue at a compound annual rate of at least 5% per year through mid-decade.

The company will depend on a combination of established medicines, innovative treatments, and novel, breakthrough therapeutics like CAR-T drugs and gene therapies to achieve the set goals.

Source Credits- 

https://money.usnews.com/investing/news/articles/2021-11-18/j-j-sees-potential-for-14-new-multibillion-dollar-drugs-by-2025

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Saudi Aramco, Reliance call off proposed USD 15 Bn investment deal

Saudi Aramco, Reliance call off proposed USD 15 Bn investment deal

By Nikita Chaurasia

Leading oil exporter Saudi Aramco and Indian multinational conglomerate firm Reliance Industries Ltd. (RIL) reportedly called off a proposed USD 15 billion deal due to valuation concerns of Reliance's oil-to-chemicals (O2C) business. Aramco had ...

U.S. consumer spending beats expectations amidst heating inflation

U.S. consumer spending beats expectations amidst heating inflation

By Nikita Chaurasia

Consumer spending in the United States rose more than predicted in October with continuous purchasing of automobiles and various other products, with no indications of slowing down due to high inflation, further supporting the much-needed economic bo...

Oil prices stable at USD 80 per barrel as U.S. taps emergency reserves

Oil prices stable at USD 80 per barrel as U.S. taps emergency reserves

By Nikita Chaurasia

Oil prices were steady at around USD 80 per barrel after the United States announced to have released 50 million oil barrels from its reserves to ease the post-COVID-19 situation. The development echoes similar moves by other nations such as Great Br...